Clinical trial
Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock…
NCT00027131 · UConn Health, Other · Terminated
Key facts
| NCT number | NCT00027131 |
|---|---|
| Title | Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70 |
| Official title | Vaccination Against High Risk Breast Cancer With Autologous Tumor-Derived Heat Shock Protein 70-Peptide Complexes (HSP70) |
| Lead sponsor | UConn Health, Other |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Biological |
| Interventions | Heat Shock Protein 70-peptide complexes (HSP70) |
| Enrollment | 15 |
| Start date | Dec 1, 2000 |
| Completion | Oct 1, 2002 |
| First posted | Nov 28, 2001 |
| Last update posted | Oct 8, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: